Recombinant human soluble thrombomodulin protects against brain injury in a CVST rat model, via downregulation of the HMGB1-RAGE axis

Gu,Jian‑Jun; Chen,Jie‑Bin; Zhang,Jian‑He; Zhang,Hao; Wang,Shou‑Sen

doi:10.3892/mmr.2016.5891

Recombinant human soluble thrombomodulin protects against brain injury in a CVST rat model, via downregulation of the HMGB1-RAGE axis

Authors:
- Jian‑Jun Gu
- Jie‑Bin Chen
- Jian‑He Zhang
- Hao Zhang
- Shou‑Sen Wang
View Affiliations

Affiliations: Department of Neurosurgery, Fuzhou General Hospital, Xiamen University Medical College, Fuzhou, Fujian 350025, P.R. China, Department of Pediatrics, Taizhou People's Hospital Affiliated to the Medical College of Nantong University, Taizhou, Jiangsu 225300, P.R. China
Published online on: October 26, 2016 https://doi.org/10.3892/mmr.2016.5891
Pages: 5217-5222

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cerebral venous sinus thrombosis (CVST) is a distinct cerebrovascular disorder, and ~50% of CVST patients progress to cerebral venous infarction, resulting in elevation of cerebral venous pressure. Anticoagulation is the standard initial treatment and is associated with a reduced relative risk of mortality and dependency. Recombinant human soluble thrombomodulin (rhs‑TM) is a promising therapeutic natural anticoagulant comparable to antithrombin, tissue factor pathway inhibitor, and activated protein C. The present study aimed to investigate the protective effects of rhs‑TM in a CVST rat model, and identify any underlying mechanisms. Rats were treated with rhs‑TM intravenously prior to CVST. Following neurological function evaluation, animals were sacrificed and brain water content and infarct volume were assessed. Brain tissue was collected from the infarcted segments and mRNA and protein expression levels of high mobility group box 1 (HMGB1), receptor for advanced glycation end products (RAGE), tumor necrosis factor (TNF)‑α, interleukin (IL)‑1β, IL‑6, caspase‑3, B‑cell lymphoma‑2 and Bcl‑2 associated X were analyzed by reverse transcription-quantitative polymerase chain reaction and western blot analysis. rhs‑TM significantly prevented neurological deficits in locomotor function and reduced infarct volume. The expression levels of HMGB1‑RAGE were upregulated in the infarcted segments of rat brains following CVST. Pretreatment with rhs‑TM inhibited the HMGB1‑RAGE axis, alleviating the expression levels of the proinflammatory cytokines, TNF‑α, IL‑1β and IL‑6; however, expression levels of the apoptosis-associated genes and proteins remained unaffected. The results of the present study indicated that rhs‑TM protects against CVST in the rat model via inhibition of the HMGB1‑RAGE axis and inflammation, but not via apoptosis.

View Figures

View References

1	Bousser MG and Ferro JM: Cerebral venous thrombosis: An update. Lancet Neurol. 6:162–170. 2007. View Article : Google Scholar : PubMed/NCBI
2	Ruiz-Sandoval JL, Chiquete E, Bañuelos-Becerra LJ, Torres-Anguiano C, González-Padilla C, Arauz A, León-Jiménez C, Murillo-Bonilla LM, Villarreal-Careaga J, Barinagarrementería F, et al: Cerebral venous thrombosis in a Mexican multicenter registry of acute cerebrovascular disease: The RENAMEVASC study. J Stroke Cerebrovasc Dis. 21:395–400. 2012. View Article : Google Scholar : PubMed/NCBI
3	Schaller B and Graf R: Cerebral venous infarction: The pathophysiological concept. Cerebrovasc Dis. 18:179–188. 2004. View Article : Google Scholar : PubMed/NCBI
4	Guenther G and Arauz A: Cerebral venous thrombosis: A diagnostic and treatment update. Neurologia. 26:488–498. 2011. View Article : Google Scholar : PubMed/NCBI
5	Camerlingo M, Salvi P, Belloni G, Gamba T, Cesana BM and Mamoli A: Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. Stroke. 36:2415–2420. 2005. View Article : Google Scholar : PubMed/NCBI
6	Esmon CT and Owen WG: Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA. 78:2249–2252. 1981. View Article : Google Scholar : PubMed/NCBI
7	Lane DA, Philippou H and Huntington JA: Directing thrombin. Blood. 106:2605–2612. 2005. View Article : Google Scholar : PubMed/NCBI
8	Conway EM, Van de Wouwer M, Pollefeyt S, Jurk K, Van Aken H, De Vriese A, Weitz JI, Weiler H, Hellings PW, Schaeffer P, et al: The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med. 196:565–577. 2002. View Article : Google Scholar : PubMed/NCBI
9	Su EJ, Geyer M, Wahl M, Mann K, Ginsburg D, Brohmann H, Petersen KU and Lawrence DA: The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model. J Thromb Haemost. 9:1174–1182. 2011. View Article : Google Scholar : PubMed/NCBI
10	Ryang YM, Dang J, Kipp M, Petersen KU, Fahlenkamp AV, Gempt J, Wesp D, Rossaint R, Beyer C and Coburn M: Solulin reduces infarct volume and regulates gene-expression in transient middle cerebral artery occlusion in rats. BMC Neurosci. 12:1132011. View Article : Google Scholar : PubMed/NCBI
11	Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC and Moskowitz MA: Effect of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science. 265:1883–1885. 1994. View Article : Google Scholar : PubMed/NCBI
12	Weimar C: Diagnosis and treatment of cerebral venous and sinus thrombosis. Curr Neurol Neurosci Rep. 14:4172014. View Article : Google Scholar : PubMed/NCBI
13	Esmon CT: The protein C pathway. Chest. 124:(Suppl 3). 26S–32S. 2003. View Article : Google Scholar : PubMed/NCBI
14	Wenzel J, Assmann JC and Schwaninger M: Thrombomodulin-a new target for treating stroke at the crossroad of coagulation and inflammation. Curr Med Chem. 21:2025–2034. 2014. View Article : Google Scholar : PubMed/NCBI
15	Van de Wouwer M, Plaisance S, De Vriese A, Waelkens E, Collen D, Persson J, Daha MR and Conway EM: The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost. 4:1813–1824. 2006. View Article : Google Scholar : PubMed/NCBI
16	Ito T and Maruyama I: Thrombomodulin: Protectorate God of the vasculature in thrombosis and infiammation. J Thromb Haemost. 9:(Suppl 1). S168–S173. 2011. View Article : Google Scholar
17	Lai CH, Shi GY, Lee FT, Kuo CH, Cheng TL, Chang BI, Ma CY, Hsu FC, Yang YJ and Wu HL: Recombinant hman thrombomodulin suppresses experimental abdominal aortic aneurysms induced by calcium chloride in mice. Ann Surg. 258:1103–1110. 2013. View Article : Google Scholar : PubMed/NCBI
18	Javanmard SH, Shahsavarzadeh T and Saadatnia M: Soluble thrombomodulin and endothelial cell protein C receptor levels in patients with cerebral venous and sinus thrombosis. Eur Neurol. 70:156–158. 2013. View Article : Google Scholar : PubMed/NCBI
19	Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191–195. 2002. View Article : Google Scholar : PubMed/NCBI
20	Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, Kaya Z, Buss S, Autschbach F, Pleger ST, Lukic IK, et al: High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation. 117:3216–3226. 2008. View Article : Google Scholar : PubMed/NCBI
21	Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, Uchimura T, Ida N, Yamazaki Y, Yamada S, et al: The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest. 115:1267–1274. 2005. View Article : Google Scholar : PubMed/NCBI
22	Tsung A, Klune JR, Zhang X, Jeyabalan G, Cao Z, Peng X, Stolz DB, Geller DA, Rosengart MR and Billiar TR: HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med. 204:2913–2923. 2007. View Article : Google Scholar : PubMed/NCBI
23	Rauvala H and Rouhiainen A: Physiological and pathophysiological outcomes of the interactions of HMGB1 with cell surface receptors. Biochim Biophys Acta. 1799:164–170. 2010. View Article : Google Scholar : PubMed/NCBI
24	Schmidt AM, Yan SD, Yan SF and Stern DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 108:949–955. 2001. View Article : Google Scholar : PubMed/NCBI
25	Ito T, Kawahara K, Okamoto K, Yamada S, Yasuda M, Imaizumi H, Nawa Y, Meng X, Shrestha B, Hashiguchi T and Maruyama I: Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol. 28:1825–1830. 2008. View Article : Google Scholar : PubMed/NCBI
26	Yang H, Meng Z, Zhang C, Zhang P and Wang Q: Establishing a new rat model of central venous sinus thrombosis and analyzing its pathophysiological and apoptotic changes. J Neurosci Methods. 203:130–135. 2012. View Article : Google Scholar : PubMed/NCBI